Table 2.
Drug | Target | MOA | Reference |
---|---|---|---|
Omalizumab | IgE | Lowers free IgE levels | Clayton 201450 |
Mepolizumab | IL-5 | Stops IL-5 from binding to its receptor on the surface of eosinophils and decreases eosinophil accumulation | Straumann 201092; Assa’ad 201193; Otani 201395 |
Reslizumab | IL-5 | Blocks IL-5 signaling on eosinophils and eosinophil accumulation | Spergel 201294; Markowitz 2018127 |
Benralizumab | IL-5 receptor alpha | Blocks IL-5 signaling; induces eosinophil apoptosis via NK cell–mediated antibody-dependent cellular cytotoxicity | Bleecker 2016128; Kolbeck 2010129 |
Cendakimab (RPC4046) | IL-13 | Binds to the IL-13 ligand, inhibits binding to IL-13Rα1 and IL-13Rα2 subunits | Hirano 2019130; Dellon 2021119 |
Dupilumab | IL-4 receptor alpha | Blocks signaling of IL-4 and IL-13 that contribute to type 2 inflammation in EoE | Hirano 202014 |
Lirentelimab (AK002) | Siglec8 | Blocks Siglec8 signaling, leading to eosinophil depletion and mast cell inhibition | Dellon 2020131 |
Etrasimod | S1P receptor | Modulates S1P receptor signaling to block lymphocyte trafficking to sites of inflammation |
S1P, sphingosine 1 phosphate; Siglec8, sialic acid–binding Ig-like lectin 8.